News

Maintenance Tacrolimus for Eczema Boosts Quality of Life

Author and Disclosure Information

 

AT THE EADV CONGRESS

References

In other outcomes, patients reported that it took a mean of 35 and median of 27 days on twice-daily therapy to become free of atopic dermatitis.

“This is helpful information for us in telling new patients what to expect. They come in really hoping to be free of eczema after 2 days. If we inform them it will take several weeks they’ll probably be more adherent to therapy,” Dr. Holm said.

Once patients became clear or almost clear and switched to twice weekly maintenance therapy, they stayed that way for an average of 61 days.

Self-reported patient compliance with the maintenance regimen was excellent. Patients indicated they applied topical tacrolimus a median of two times per week. They also utilized emolliants an average of once per day or more, as physicians had encouraged. Patients didn’t report any adverse events on their questionnaires.

An interesting study finding was that even though 52% of patients had atopic dermatitis on the face -- the most visible and highly charged of all locations -- 75% of patients indicated the biggest difficulty posed by their skin disease was its itchiness, not its adverse impact on their appearance.

“This is what I find in my own daily practice, too. Patients come in and say, ‘Please give me a drug to remove my daily itch and I will be satisfied,’” according to Dr. Holm.

The study was sponsored by Astellas Pharma. Dr. Holm is a consultant to the company.

Pages

Recommended Reading

Hair Loss in a 12-Year-Old
Clinician Reviews
Skin Cancer Treatment Costs Skyrocket Over Past Decade
Clinician Reviews
Chronic Inflammatory Disease Patients at Greater Risk of Major CV Events
Clinician Reviews
Retired Tour Guide Intends to Maintain Her Tan
Clinician Reviews
Irritated and Downright Painful
Clinician Reviews
New Law Will Speed Sunscreen Ingredient Approval
Clinician Reviews
Psoriasis Is Independently Associated With Advanced Liver Fibrosis
Clinician Reviews
FDA Warns of Potentially Fatal Skin Reaction With Ziprasidone
Clinician Reviews
Early Discoid Lupus Onset Protective Against Nephritis
Clinician Reviews
Dupilumab Advances for Severe Atopic Dermatitis
Clinician Reviews